168 related articles for article (PubMed ID: 36045613)
1. Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5.
Collins JM; Nworu AC; Mohammad SJ; Li L; Li C; Li C; Schwendeman E; Cefalu M; Abdel-Rasoul M; Sun JW; Smith SA; Wang D
Clin Transl Sci; 2022 Nov; 15(11):2720-2731. PubMed ID: 36045613
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
4. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
5. Statin regulation of CYP3A4 and CYP3A5 expression.
Willrich MA; Hirata MH; Hirata RD
Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
7. Cis-acting regulatory elements regulating CYP3A4 transcription in human liver.
Collins JM; Wang D
Pharmacogenet Genomics; 2020 Jul; 30(5):107-116. PubMed ID: 32301865
[TBL] [Abstract][Full Text] [Related]
8. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
9. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
[TBL] [Abstract][Full Text] [Related]
11. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
Willrich MA; Rodrigues AC; Cerda A; Genvigir FD; Arazi SS; Dorea EL; Bernik MM; Bertolami MC; Faludi A; Largura A; Baudhuin LM; Bryant SC; Hirata MH; Hirata RD
Clin Chim Acta; 2013 Jun; 421():157-63. PubMed ID: 23501331
[TBL] [Abstract][Full Text] [Related]
15.
Yang W; Zhao H; Dou Y; Wang P; Chang Q; Qiao X; Wang X; Xu C; Zhang Z; Zhang L
Drug Metab Dispos; 2023 Apr; 51(4):492-498. PubMed ID: 36623883
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.
Kuypers DR; de Loor H; Naesens M; Coopmans T; de Jonge H
Pharmacogenet Genomics; 2014 Dec; 24(12):597-606. PubMed ID: 25322286
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.
Liu H; Xu Q; Huang W; Zhao Q; Jiang Z; Kuang X; Li Z; Sun H; Qiu X
Eur J Clin Pharmacol; 2019 Nov; 75(11):1533-1540. PubMed ID: 31401678
[TBL] [Abstract][Full Text] [Related]
18. Newly identified cytochrome P450 3A genes of tree shrews and pigs are expressed and encode functional enzymes.
Uno Y; Jikuya S; Noda Y; Oguchi A; Murayama N; Kawaguchi H; Tsukiyama-Kohara K; Yamazaki H
Comp Biochem Physiol C Toxicol Pharmacol; 2023 May; 267():109579. PubMed ID: 36822299
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
20. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
